Data on SAR-bisPSMA to be presented at EANM

• Clarity Pharmaceuticals to present SAR-bisPSMA data at EANM Annual Congress
• 64Cu-SAR-bisPSMA shows improved diagnostic performance over current SOC
• Case reports highlight 67Cu-SAR-bisPSMA's therapeutic potential in mCRPC
• Positive feedback from patients and clinicians on SAR-bisPSMA's impact

Clarity Pharmaceuticals (ASX: CU6) announced the acceptance of data on 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for presentation at the EANM Annual Congress 2026. The data includes a top-rated oral presentation from the Co-PSMA trial, showing 64Cu-SAR-bisPSMA's superior diagnostic performance over current SOC. Case reports also highlight 64Cu-SAR-bisPSMA's ability to detect prostate cancer recurrence where SOC failed. Additionally, data from the SECuRE trial demonstrates 67Cu-SAR-bisPSMA's therapeutic potential in mCRPC, with participants achieving undetectable disease. Both products have shown promising results with mostly mild adverse events.